CathRx Ltd is an Australian medical device company developing and commercializing innovative cardiac catheters for use in the diagnosis and treatment of cardiac arrhythmias. Sales of mapping, temporary pacing and ablation catheters began in Europe during 2008. Additionally, the company is developing devices for the treatment of atrial fibrillation – an arrhythmia that is currently poorly treated. The worldwide market potential for a successful atrial fibrillation device is in excess of $3 billion.
George Murphy was a director of CathRx from 2003 to 2005, leveraging his experience as a founder of EP Technologies in 1988, a company that pioneered arrhythmia diagnosis and treatment, and was bought by Boston Scientific. TASCF co-invested in CathRx’s first round financing with CM Capital, a Brisbane-based venture firm affiliated with CIBC. The Company is listed on the Australian Securities Exchange where it is traded under the symbol CXD.